JP Morgan analyst Jeffrey J. Zekauskas downgraded the rating for Eastman Chemical Company (NYSE:EMN) from Overweight to Neutral and cut the price forecast from $112.00 to $76.00. On April 25, the company reported first-quarter adjusted EPS of $1.91, beating the $1.89 estimate, while sales of $2.29 billion missed the $2.33 billion estimate. For the second quarter, Eastman anticipates adjusted EPS of $1.70-$1.90, below the consensus estimate of $2.18. The company expects a slight sequential volume increase across its markets in the second quarter, but it is less than typical due to trade uncertainty. Additionally, second-quarter earnings are expected to be negatively impacted by U.S.-China tariffs and increased planned maintenance. The analyst remarks that typically, Eastman sees a second-quarter volume and earnings increase due to seasonal construction. Zekauskas writes that tariffs haven’t directly impacted Eastman’s operations because customers are currently using material already within the country. Further, the analyst says that sustained difficult trade conditions could increase near-term earnings risk and diminish longer-term growth prospects. The analyst estimates the company’s specialty polymer sales to China to be ~$340 million, generating ~$100 million in EBITDA. While Eastman forecasts $1.2 billion in 2025 cash flow from operations, this may be aggressive given the $167 million cash use in the first quarter, adds the analyst. Consequently, the analyst lowered the EPS estimate to $7.40 (from $8.45) for 2025 and $7.80 (from $9.00) for 2026. Considering current conditions, a further ~$1.00/share reduction to the base case 2025 earnings range ($7.00-$7.75) seems appropriate, adds the analyst. Zekauskas adds that this could potentially reflect less pressure on the second half of 2025 filter tow earnings as destocking effects ease. Price Action: EMN shares are down 0.84% at 475.20 at the last check Monday. Read Next: Trump Administration Fast-Tracks Ten Domestic Critical Mineral Projects Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? EASTMAN CHEMICAL (EMN): Free Stock Analysis Report This article JP Morgan Cautions Trade Tensions Are Weighing On Eastman Chemical Growth Prospects originally appeared on Benzinga.com © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
JP Morgan Cautions Trade Tensions Are Weighing On Eastman Chemical Growth Prospects
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...